10-Q: Waters Corp. Reports Strong Q2 Sales, Eyes Major BD Merger

Waters Corporation reported a 9% increase in Q2 2025 net sales and a 3% rise in net income, while announcing a transformative $17.5 billion merger with BD's Biosciences & Diagnostic Solutions business.

Summary

• Total net sales increased by 9% to $771.3 million for the three months ended June 28, 2025, compared to $708.5 million in the prior year period.
• Net income for the second quarter of 2025 rose 3% to $147.1 million, up from $142.7 million in the same period last year.
• Diluted net income per common share increased 3% to $2.47 for Q2 2025, compared to $2.40 in Q2 2024.
• For the six months ended June 28, 2025, total net sales grew 7% to $1.43 billion, and net income increased 10% to $268.5 million.
• Operating income for Q2 2025 slightly decreased by less than 1% to $188.2 million, primarily due to $14 million in merger transaction costs and $5 million in ERP system implementation expenses.
• The company entered into a definitive agreement on July 13, 2025, to acquire Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business for approximately $17.5 billion in a Reverse Morris Trust transaction.
• The acquisition of Halo Labs LTD was completed on May 20, 2025, for $35 million, enhancing biopharmaceutical formulation and quality control tools.
• Sales in China increased 17% in Q2 2025, partly due to an estimated $8 million pull-forward of chemistry consumable sales ahead of new tariffs.
• Sales to pharmaceutical customers increased 11% in Q2 2025, driven by growth in China, the Americas, and Europe.
• The company reduced its senior unsecured revolving credit facility capacity by $200 million to $1.8 billion, with $200 million outstanding as of June 28, 2025.
• Net cash provided by operating activities decreased to $301 million in H1 2025 from $317 million in H1 2024, primarily due to higher tax payments and ERP implementation costs.

Sentiment

Score: 7

Explanation: The company delivered solid financial results with strong revenue and net income growth, particularly in its core Waters segment and key geographic markets. The strategic acquisition of Halo Labs and the planned transformative merger with BD's Biosciences & Diagnostic Solutions business present significant long-term growth opportunities. However, the slight decline in operating income for Q2 due to merger-related and ERP implementation costs, the decline in U.S. sales, and the substantial increase in debt associated with the BD merger introduce considerable near-term integration and financial risks. The overall sentiment is positive due to the underlying business strength and strategic expansion, but tempered by the scale and complexity of the upcoming merger.

Positives

• Strong overall net sales growth of 9% in Q2 2025 and 7% in H1 2025, driven by broad-based customer demand across most major geographies and end markets.
• Net income and diluted EPS increased by 3% in Q2 2025 and 10% (net income) / 9% (diluted EPS) in H1 2025.
• Significant growth in Waters instrument systems sales (7% in Q2, 9% in H1) and chemistry consumables (17% in Q2, 10% in H1), particularly in mass spectrometry.
• Robust sales growth in China (17% in Q2, 12% in H1) and Europe (14% in Q2, 7% in H1).
• Pharmaceutical customer sales increased by 11% in Q2 2025, indicating strong demand from a key market segment.
• Interest expense, net, decreased by $10 million in Q2 2025 and $20 million in H1 2025 due to lower average outstanding debt.
• No litigation provisions were recorded in H1 2025, compared to $10 million in H1 2024.
• The acquisition of Halo Labs LTD strategically expands the company's biopharmaceutical product quality control offerings.
• The Singapore Development and Expansion Incentive provides a concessionary income tax rate of 5%, increasing net income by $1.5 million in H1 2025.

Negatives

• Operating income decreased by less than 1% in Q2 2025, impacted by $14 million in transaction costs related to the BD merger and $5 million for ERP system implementation.
• Operating income as a percentage of sales declined to 24.4% in Q2 2025 from 26.7% in Q2 2024, and to 23.7% in H1 2025 from 24.0% in H1 2024.
• Sales in the United States declined by 1% in Q2 2025.
• TA instrument systems sales declined by 5% in Q2 2025, primarily due to a 21% decrease in U.S. sales.
• Net cash provided by operating activities decreased by $16 million in H1 2025, partly due to $24 million more in tax payments and $18 million in ERP implementation costs.
• The increase in inventory (up $35.7 million in H1 2025) was attributed to higher material costs and increased safety stock levels, which could tie up capital.
• The estimated $8 million pull-forward of chemistry consumable sales in China due to anticipated tariffs may negatively impact future sales in that region.

Risks

• The consummation of the BD merger is subject to significant risks and uncertainties, including regulatory approvals, Waters Corporation shareholder approval, and receipt of an IRS private letter ruling.
• There is no assurance that the BD merger will be completed on the expected terms, timeline, or at all, with potential for increased transaction costs and business disruptions if delayed.
• A termination fee of $733 million is payable to BD if the merger agreement is terminated under certain circumstances.
• Failure to successfully integrate BD's Biosciences and Diagnostic Solutions business could adversely affect the combined company's future results and ability to realize anticipated benefits and synergies.
• The substantial increase in indebtedness (approximately $4 billion assumed debt from SpinCo and potential $1.8 billion for Waters Special Dividend) following the merger could reduce financial flexibility, lower credit ratings, and increase borrowing costs.
• Foreign currency exchange rate fluctuations, particularly a strengthening U.S. dollar, could negatively impact non-U.S. operating results and the fair market value of cash held in foreign currencies.
• Global economic, sovereign, and political conditions, including new tariffs, trade regulations, inflation, interest rates, and geopolitical conflicts, pose ongoing uncertainties.
• Economic conditions in China, trade tensions, increased local competition, and government procurement restrictions present significant challenges in the Chinese market.
• The company's ability to access capital, maintain liquidity, and service its debt in volatile market conditions is a risk.
• Changes in customer demand and funding availability can impact product sales.
• Competition from new products, loss of market share, and price pressures from competitors are ongoing risks.
• Regulatory, economic, and competitive obstacles to new product introductions and the inability to grow organically through innovation are concerns.
• Risks related to the development, deployment, and effective use of artificial intelligence (AI) could impact competitiveness.
• Unexpected disruptions in operations, including those associated with the transition to a new ERP system, could occur.
• Failure to adequately protect intellectual property, infringement claims, and inability to obtain licenses on reasonable terms are risks.
• Reliance on outside contractors for components and modules, and potential supply chain disruptions, could affect operations.
• Increased regulatory burdens, especially from agencies like the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, could impact the business.
• Litigation and other legal and regulatory proceedings could have an adverse effect on financial position or results of operations.

Future Outlook

The company anticipates the transformative merger with BD's Biosciences & Diagnostic Solutions business to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals. It expects to incur approximately $120 million in transaction-related expenses and financing fees if the merger closes, and will assume approximately $4 billion of incremental debt. The company also plans to spend approximately $130 million on a new worldwide ERP system implementation over the next three years. It expects interest rate swap agreements to lower net interest expense by approximately $10 million in 2025. The company is evaluating the impact of the recently enacted US 'One Big Beautiful Tax Bill Act' on its financial position.

Management Comments

• Management believes the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods.
• Management believes it has meritorious arguments in its current litigation matters and believes any outcome, either individually or in the aggregate, will not be material to the company's financial position, results of operations or cash flows.
• The company believes that actions and policies will mitigate a substantial portion of the impact of tariffs, but cannot provide any assurances that tariffs or any resulting impediments to trade will not have a material effect on the company's consolidated statement of operations and statement of cash flows.

Industry Context

The company operates in the analytical instrument industry, a sector driven by innovation in chromatography, mass spectrometry, and thermal analysis, serving life, materials, and food sciences. The announced merger with BD's Biosciences & Diagnostic Solutions business signifies a major strategic move to create a leading global life sciences and diagnostics company, aiming for enhanced scale, complementary capabilities, and expanded end-market exposure. This aligns with a trend towards consolidation and diversification within the broader life sciences and diagnostics market, seeking to leverage combined R&D, distribution, and customer bases. The company's strong performance in pharmaceutical customer sales reflects continued investment and demand in drug discovery and development, while the decline in U.S. industrial sales for TA instruments suggests some regional or segment-specific headwinds within the industrial sector.

Corporate Governance

Legal Proceedings

• No material changes in legal proceedings during the six months ended June 28, 2025.
• No litigation provisions were recorded by the company during the six months ended June 28, 2025, compared to $10 million in patent litigation settlement provisions and related costs in the prior year period.

Stakeholder Impact

• Shareholders: Potential for dilution from new share issuance in the BD merger, but also potential for long-term value creation from enhanced scale and capabilities. Share repurchase program extension offers continued capital return potential. Stock price volatility is expected due to merger pendency.
• Employees: Merit compensation increases were noted, but the BD merger and ERP implementation could lead to organizational changes and integration challenges.
• Customers: Increased product demand across most major geographies and end markets, particularly in the pharmaceutical sector. The Halo Labs acquisition and the BD merger aim to expand product offerings and capabilities, potentially benefiting customers with broader solutions.
• Creditors: The company's debt levels will substantially increase with the BD merger, potentially impacting credit ratings and borrowing costs, though the company remains in compliance with current debt covenants.

Next Steps

• Complete the integration of Halo Labs LTD into the company's operations.
• Proceed with the definitive agreement to purchase and combine Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business, targeting a close around the end of the first quarter of calendar year 2026.
• Obtain required regulatory approvals and Waters Corporation shareholder approval for the BD merger.
• Continue the implementation of the new worldwide enterprise resource planning (ERP) system, with anticipated spending of approximately $130 million over the next three years.
• Monitor the adoption of Pillar Two global minimum tax rules in additional jurisdictions.
• Evaluate the impact of the recently enacted US 'One Big Beautiful Tax Bill Act' (OBBB) on the company's financial position, results of operations, and cash flows.
• Continue to manage foreign currency exchange rate exposures through hedging strategies.

Key Dates

Recommendation

Waters Corporation delivered solid financial performance in Q2 and H1 2025, demonstrating healthy revenue and net income growth driven by strong demand in key segments and geographies. The strategic acquisition of Halo Labs and the planned transformative merger with BD's Biosciences & Diagnostic Solutions business are significant long-term growth catalysts, promising enhanced scale and complementary capabilities. However, the BD merger introduces substantial financial and operational risks, including the assumption of significant debt (approximately $4 billion) and potential integration challenges. The short-term impact on operating income from merger-related and ERP implementation costs, along with regional sales declines in the U.S. and the 'pull-forward' effect in China, warrant caution. Given the balance of strong underlying performance and the considerable uncertainties and complexities associated with the large-scale BD merger, a 'hold' recommendation is appropriate for a seasoned investor. It allows for observation of merger progress, integration success, and the actual financial impact before making a more definitive investment decision.

Keywords

Analytical Instruments, Mass Spectrometry, Chromatography, Life Sciences, Biopharmaceutical, Laboratory Equipment, SEC Filing, Quarterly Report, Merger, Acquisition, Financial Results, WAT